Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Caitlin Cronin maintains a Buy rating on TELA Bio (NASDAQ:TELA) but lowers the price target from $14 to $12.
August 13, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on TELA Bio but lowers the price target from $14 to $12.
The Buy rating suggests continued confidence in TELA Bio's long-term prospects, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100